Breyer Capital
VC Fund
Menlo Park, United States
Breyer Capital is a premier global venture capital and private equity investor focused on catalyzing high-impact entrepreneurs in the United States and China. Founded by Jim Breyer in 2006, Breyer Capital makes long-term, idea-driven strategic investments in its chosen core areas: social media, entertainment/media, digital health, and financial technologies. Breyer Capital actively partners with a diverse set of companies including early-stage startups building breakthrough technologies, fast growing companies, and established worldwide leading corporations. Its team enjoys helping to frame strategic investments anchored by the passion of founders and owner/operator teams, the insights of its network of world-class investors, and a conviction that artificial intelligence, machine learning, and virtual reality will transform technology and investment opportunities globally.
- Total investments:
- 223
- Last investment:
- Lead investor:
- 22%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Breyer Capital invests in
Stages Breyer Capital invests in
Countries Breyer Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $4M–$22M
- Series A
- $10M–$48M
- Series B
- $20M–$135M
Investment Focus
Industry
- Health Care 34 (15%)
- Artificial Intelligence 30 (13%)
- Software 28 (13%)
- Financial Services 24 (11%)
- Information Technology 21 (9%)
Stage
- Series A 49 (22%)
- Series B 41 (18%)
- Seed 38 (17%)
- Series C 18 (8%)
- Series D 14 (6%)
Country
- United States 109 (49%)
- United Kingdom 5 (2%)
- Kenya 3 (1%)
- Singapore 3 (1%)
- Ghana 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Daniel Breyer
Investor
|
Investor | Total investments: 0 | Find email | |
Tom Johnson
Founder & CEO
|
Founder & CEO | Total investments: 105 | Find email | |
Leo Grady
CEO in Residence
|
CEO in Residence | Total investments: 2 | Find email | |
Morgan Cheatham
Head of health care and life sciences
|
Head of health care and life sciences | Total investments: 8 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | $135M / Series B / Oct 13, 2026 | ||
| Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools. | $50M / Venture - Series Unknown / Aug 19, 2026 | ||
| Onyx Odds is a predictions company, specializing in sports predictions. | $20M / Series A / Jun 24, 2026 | ||
| Pathway Labs is a cardiology AI company. Its EchoNext software is an FDA cleared multi condition tool. It analyzes standard 12 lead ECGs to detect structural heart disease. The platform integrates into clinical workflows to coordinate patient care. | $8.5M / Seed / Jun 23, 2026 | ||
| Catena Labs incubate independent products spanning identity, communications, AI, and commerce. The company's mission is to empower people with agency, safety, value, and joy online. | $30M / Series A / May 20, 2026 | ||
| ParcelBio is a company that creating a programmable method for safely and precisely delivering mRNA to many cell types in the body. | $13M / Seed / May 07, 2026 | ||
| Simplified Financial Solutions Company offers startups and SMEs financial management solutions including the ability to issue virtual and physical corporate cards, manage spending and automate expense reporting. | $20M / Series A / Feb 09, 2026 | ||
| Soley Therapeutics combines AI with molecular and cellular response detection for developing new efficacious drugs, using image acquisition-based approaches.Soley Therapeutics has taken an orthogonal approach to discover new drugs by developing a technology platform to measure how cells respond multi-dimensionally in response to drugs. We havedeveloped a novel platform for high-content phenotypic drug screening, where the drug effect on a cell can be visualized via molecular-microscopic images and analyzed by using sophisticated AI tools. | $200M / Series C / Jan 07, 2026 | ||
| Harbor Health is a multi-specialty clinic group that provides smarter health care using technology. The company co-creates a health path that is dedicated to knowing individuals' health goals with the guidance of specialists when needed. Harbor Health was founded in 2022 and is based in Austin, Texas. | $130M / Series B / Sep 09, 2025 | ||
| Hemi (https://hemi.xyz) is a modular protocol that integrates Bitcoin and Ethereum to amplify and extend the core capabilities of the two leading blockchain networks. This offers a novel perspective on blockchain interoperability and scaling by approaching Bitcoin and Ethereum as components of a single supernetwork. The result providessecurity that exceeds that of Bitcoin (“superfinality”) and new levels of blockchain programmability, portability, and potential. Hemi was co-founded by Jeff Garzik (former Bitcoin core developer) and Max Sanchez (inventor of the Proof-of-Proof consensus protocol), and is surrounded by a team of renowned blockchain engineers, strategic partners and investors. | $15M / Seed / Aug 26, 2025 | ||
| See all 223 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Breyer Capital invest in?
Breyer Capital invests primarily in Health Care, Artificial Intelligence and Software startups, most often at Series A and Series B stage. Most of the 223 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Breyer Capital invest in?
Breyer Capital typically joins rounds of $4M–$22M at Seed, $10M–$48M at Series A and $20M–$135M at Series B. These are whole funding-round sizes, not Breyer Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Breyer Capital took part in.
How do I contact Breyer Capital?
Public channels for Breyer Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Breyer Capital?
The team at Breyer Capital includes Daniel Breyer (Investor), Tom Johnson (Founder & CEO) and Leo Grady (CEO in Residence). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
